260 / 1138
ESMO Magnitude of Clinical Benefit Scale
(ESMO-MCBS)
•
Cure takes precedence over deferral of death.
•
Direct endpoints
such as
survival
and
quality of life
take
precedence over surrogates such as progression-free survival
or response rate.
•
Disease-free survival in curative disease is a more valid
surrogate than progression-free survival or response rate in
noncurative disease.
•
Interpretation of the evidence of benefit derived from surrogate
outcomes (such as progression-free survival) may be
influenced by secondary outcome data.
Cherny NI, Ann Oncol 2015